Humana (NYSE:HUM) Price Target Raised to $245.00 at Barclays

Humana (NYSE:HUM) had its price objective hoisted by investment analysts at Barclays from $234.00 to $245.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has an “equal weight” rating on the insurance provider’s stock. Barclays‘s price target would suggest a potential downside of 8.99% from the stock’s previous close.

Several other research analysts also recently commented on the company. Evercore ISI initiated coverage on Humana in a report on Monday, September 22nd. They set an “in-line” rating and a $295.00 target price on the stock. Truist Financial cut their price objective on Humana from $300.00 to $285.00 and set a “hold” rating on the stock in a research note on Monday, November 10th. KeyCorp reissued a “sector weight” rating on shares of Humana in a research report on Friday, December 12th. Wells Fargo & Company boosted their price target on shares of Humana from $344.00 to $347.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 7th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Humana in a research note on Wednesday, October 8th. Nine investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat.com, Humana has a consensus rating of “Hold” and an average price target of $294.89.

Humana Price Performance

Shares of HUM opened at $269.21 on Monday. The company has a quick ratio of 2.02, a current ratio of 2.02 and a debt-to-equity ratio of 0.68. The stock has a market cap of $32.38 billion, a PE ratio of 24.83, a PEG ratio of 2.18 and a beta of 0.45. Humana has a 12-month low of $206.87 and a 12-month high of $315.35. The business has a 50-day simple moving average of $255.49 and a two-hundred day simple moving average of $261.31.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, November 5th. The insurance provider reported $3.24 EPS for the quarter, beating analysts’ consensus estimates of $2.95 by $0.29. The firm had revenue of $32.65 billion for the quarter, compared to analyst estimates of $31.99 billion. Humana had a return on equity of 12.86% and a net margin of 1.02%.The business’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period last year, the firm posted $4.16 earnings per share. Analysts anticipate that Humana will post 16.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Humana

A number of hedge funds have recently added to or reduced their stakes in the company. Rosenberg Matthew Hamilton raised its holdings in Humana by 136.0% during the fourth quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after buying an additional 68 shares during the last quarter. Elevation Point Wealth Partners LLC bought a new stake in shares of Humana during the second quarter worth about $32,000. Mather Group LLC. acquired a new stake in shares of Humana in the 3rd quarter worth about $34,000. AlphaCore Capital LLC bought a new position in Humana in the 2nd quarter valued at about $39,000. Finally, Private Wealth Management Group LLC boosted its stake in Humana by 47.5% during the 3rd quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock valued at $39,000 after purchasing an additional 48 shares during the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.